Atria Investments Inc Raises Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Atria Investments Inc lifted its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 41.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,137 shares of the biopharmaceutical company’s stock after acquiring an additional 1,497 shares during the period. Atria Investments Inc’s holdings in Intra-Cellular Therapies were worth $376,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Perceptive Advisors LLC grew its holdings in shares of Intra-Cellular Therapies by 62.6% during the second quarter. Perceptive Advisors LLC now owns 1,716,407 shares of the biopharmaceutical company’s stock valued at $117,557,000 after buying an additional 661,052 shares during the last quarter. Millennium Management LLC lifted its holdings in shares of Intra-Cellular Therapies by 214.5% in the 2nd quarter. Millennium Management LLC now owns 889,102 shares of the biopharmaceutical company’s stock worth $60,895,000 after acquiring an additional 606,358 shares during the last quarter. Avoro Capital Advisors LLC lifted its stake in shares of Intra-Cellular Therapies by 21.2% in the 2nd quarter. Avoro Capital Advisors LLC now owns 3,000,000 shares of the biopharmaceutical company’s stock worth $205,470,000 after acquiring an additional 525,000 shares during the period. Marshall Wace LLP acquired a new stake in shares of Intra-Cellular Therapies in the second quarter valued at about $34,178,000. Finally, Hood River Capital Management LLC acquired a new position in Intra-Cellular Therapies during the second quarter worth about $33,390,000. Institutional investors own 92.33% of the company’s stock.

Intra-Cellular Therapies Stock Down 0.2 %

ITCI opened at $85.45 on Friday. The firm has a market capitalization of $9.06 billion, a P/E ratio of -98.22 and a beta of 0.97. The firm’s 50 day moving average is $78.84 and its 200-day moving average is $74.58. Intra-Cellular Therapies, Inc. has a 52-week low of $58.14 and a 52-week high of $93.45.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.07). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The company had revenue of $175.40 million during the quarter, compared to the consensus estimate of $172.30 million. During the same period in the prior year, the company posted ($0.25) EPS. Intra-Cellular Therapies’s quarterly revenue was up 39.0% on a year-over-year basis. Equities analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

Insider Transactions at Intra-Cellular Therapies

In related news, CEO Sharon Mates sold 34,396 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $72.84, for a total transaction of $2,505,404.64. Following the completion of the sale, the chief executive officer now directly owns 1,070,329 shares of the company’s stock, valued at $77,962,764.36. The trade was a 3.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, President Michael Halstead sold 22,869 shares of the company’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $89.12, for a total transaction of $2,038,085.28. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 97,778 shares of company stock worth $7,524,436. 2.60% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on ITCI shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $130.00 price objective on shares of Intra-Cellular Therapies in a report on Monday, September 16th. Morgan Stanley raised their price objective on shares of Intra-Cellular Therapies from $92.00 to $95.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. The Goldman Sachs Group dropped their target price on shares of Intra-Cellular Therapies from $77.00 to $74.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th. JPMorgan Chase & Co. boosted their price objective on Intra-Cellular Therapies from $81.00 to $89.00 and gave the stock an “overweight” rating in a report on Monday, November 4th. Finally, Piper Sandler raised Intra-Cellular Therapies from a “neutral” rating to an “overweight” rating and upped their price target for the company from $68.00 to $92.00 in a research note on Friday, September 6th. Two research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat, Intra-Cellular Therapies presently has an average rating of “Moderate Buy” and a consensus target price of $97.23.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.